0000950170-24-062599.txt : 20240520 0000950170-24-062599.hdr.sgml : 20240520 20240520185050 ACCESSION NUMBER: 0000950170-24-062599 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240516 FILED AS OF DATE: 20240520 DATE AS OF CHANGE: 20240520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAWES KAREN A CENTRAL INDEX KEY: 0001261506 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 24966438 MAIL ADDRESS: STREET 1: 579 BELLEVUE AVE CITY: NEWPORT STATE: RI ZIP: 02840 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 4 1 ownership.xml 4 X0508 4 2024-05-16 0000730272 REPLIGEN CORP RGEN 0001261506 DAWES KAREN A C/O REPLIGEN CORPORATION 41 SEYON ST., BLDG 1, STE 100 WALTHAM MA 02453 true false false false false Common Stock 2024-05-16 4 A false 803 0.00 A 88170 D Stock Option (Right to Buy) 171.03 2024-05-16 4 A false 1576 0.00 A 2025-05-16 2034-05-16 Common Stock 1576 1576 D Ms. Dawes was awarded 803 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. /s/ Kimberly Brown (Attorney in Fact) 2024-05-20